Allos Therapeutics, Inc. Announces Presentation Of Updated Results From Phase 1/2 Trial Of PDX
WESTMINSTER, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. today announced that updated results from a Phase 1/2 study evaluating the Company's novel antifolate PDX (pralatrexate) in patients with relapsed or refractory non-Hodgkin's lymphoma and Hodgkin's disease have been accepted for presentation at the American Society of Hematology's 48th Annual Meeting, to be held December 9 - 12 in Orlando.
Owen O'Connor, M.D., Ph.D., Head of the Laboratory of Experimental Therapeutics for Lymphoproliferative Malignancies, Lymphoma and Development Chemotherapy Services, Memorial Sloan-Kettering Cancer Center (MSKCC), is scheduled to report updated results from the on-going study in an oral presentation titled "Pralatrexate (PDX) Produces Durable Complete Remissions in Patients with Chemotherapy Resistant Precursor and Peripheral T-Cell Lymphomas: Results of the MSKCC Phase I/II Experience" on Monday, December 11 at 11:45 AM ET.
A copy of the abstract (#556063) is currently available on the American Society of Hematology's web site, www.hematology.org.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors. For additional information, please visit the Company's website at www.allos.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including those to be discussed in the presentation and others that can be found in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2005 and in the Company's periodic reports on Form 10-Q and Form 8-K. The Company does not undertake any obligation to update any forward-looking statements contained in the anticipated presentation as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the presentation. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.
Allos Therapeutics, Inc.CONTACT: Jennifer Neiman, Manager, Corporate Communications of AllosTherapeutics, Inc., +1-720-540-5227, jneiman@allos.com